Abingworth raises $582 million for new Clinical Co-Development Fund – Over $1 billion raised in 2021 for two funds

Asante Capital are pleased to announce the final closing of Abingworth’s new Clinical Co-Development Fund at $582 million. Abingworth Clinical Co-Development Fund 2 (ACCD 2) was significantly oversubscribed, exceeding its target of $350 million and closing at its hard cap. Alongside the recent $465 million Abingworth Bioventures (ABV 8) flagship fund, Abingworth has raised over $1 billion to invest in life science companies in the US, UK and Continental Europe developing innovative therapeutics with potential to significantly improve human health.

Asante Capital Group acted as global placement advisor for the fundraise.

Please see full Press Release here.

To read more on the Times click here.

Ricardo Felix is Appointed Partner as Hong Kong Team Grows

We're excited to announce that Asante has recently appointed Ricardo Felix, Head of Asia-Pacific, to Partner.

Asante Capital congratulates its partner on the final closing of Harbert Infrastructure Fund VI (‘HIF VI’)

We are pleased to announce the final closing of Harbert Infrastructure Fund VI ( ‘HIF VI’) on September 30, 2022. HIF VI secured $905 million in fund and related co-investment commitments to invest in HIF VI’s portfolio of North American power and renewable energy opportunities. 

Private-Equity Firms Look to Foreign Cash as U.S. Pension Funds Struggle

One of our Managing Partners, Fraser van Rensburg, was quoted in a Wall Street Journal article by Chris Cumming about American private-equity firms collecting more money from abroad.